RNA
Atrium Therapeutics, Inc.
1W: +6.2%
1M: -82.0%
3M: -81.9%
YTD: -81.8%
1Y: -57.6%
3Y: -36.2%
5Y: -50.6%
$13.09
-0.00 (-0.01%)
After Hours: $13.11 (+0.02, +0.16%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
0
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$203.1M
52W Range11.95-16.77
Volume288,519
Avg Volume1,643,675
Beta0.00
Dividend—
Analyst Ratings
Company Info
CEOKathleen Gallagher
SectorHealthcare
IndustryBiotechnology
IPO Date2026-02-27
Websiteatriumtherapeutics.com
10578 Science Center Drive
San Diego, CA 92121
US
San Diego, CA 92121
US
619 876 0700
About Atrium Therapeutics, Inc.
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Latest News
Hudson Bay Capital Management LP Sells 45,000 Shares of Avidity Biosciences, Inc. $RNA
JPMorgan Chase & Co. Purchases 319,282 Shares of Avidity Biosciences, Inc. $RNA
Boothbay Fund Management LLC Purchases 42,687 Shares of Avidity Biosciences, Inc. $RNA
Avoro Capital Advisors LLC Has $333.09 Million Stock Holdings in Avidity Biosciences, Inc. $RNA
Avidity Biosciences, Inc. (NASDAQ:RNA) Receives $69.57 Consensus Price Target from Brokerages
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Hughes Steven George | S-Sale | 2,017 | $72.45 | 2026-01-21 |
| Hughes Steven George | S-Sale | 2,878 | $72.45 | 2026-01-21 |
| Boyce Sarah | S-Sale | 6,394 | $72.45 | 2026-01-21 |
| Boyce Sarah | S-Sale | 7,993 | $72.45 | 2026-01-21 |
| Flanagan W. Michael | S-Sale | 3,976 | $72.45 | 2026-01-21 |